Scientific advances during the past 25 years have vastly improved clinicians’ abilities to diagnose and treat patients. Yet despite rapid expansion of cell and gene therapies, manufacturing inefficiencies and regulatory issues hinder broad access to these potentially life-saving therapies.
In this case study we explore how Northeastern’s BATL improved analytical methods by streamlining providers and developing a single collaborative partnership with Thermo Fisher Scientific.
Download our case study to learn about:
- BATL’s mission of enabling biopharmaceutical education, global regulatory convergence, industry partnerships, and use-inspired research for the benefit of patients worldwide
- Challenges associated with equipping an educational lab to inform real-world cell and gene therapy development
- Benefits available by partnering with Thermo Fisher Scientific for full cell and gene therapy workflow support